The role of shared genetic risk in the etiology of type 1 diabetes (T1D) and type 2 diabetes (T2D) 14 and the mechanisms of these effects is unknown. In this study, we generated T1D association 15 data of 15k samples imputed into the HRC reference panel which we compared to T2D 16 association data of 159k samples imputed into 1000 Genomes. The effects of genetic variants on 17 T1D and T2D risk at known loci and genome-wide were positively correlated, which we replicated 18 using data from the UK Biobank and clinically-defined diabetes in the WTCCC. Increased risk of 19 T1D and T2D was correlated with higher fasting insulin and fasting glucose level and decreased 20 birth weight, among T1D-and T2D-specifc correlations, and T1D and T2D associated variants 21 were enriched in regulatory elements for pancreatic, insulin resistance (adipose, CD19+ B cell), 22 and developmental (CD184+ endoderm) cell types. We fine-mapped causal variants at known 23 T1D and T2D loci and found evidence for co-localization at five signals, four of which had same 24 direction of effect, including CENPW and GLIS3. Shared risk variants at GLIS3 and other signals 25 were associated with measures of islet function, while CENPW was associated with early growth, 26 and we identified shared risk variants at GLIS3 in islet accessible chromatin with allelic effects on 27 islet regulatory activity. Our findings support shared genetic risk involving variants affecting islet 28 function as well as insulin resistance, growth and development in the etiology of T1D and T2D. 29 30 31 32 33 34 35 36
Introduction
We then determined the relationship between variant effects on T1D and T2D risk by comparing 102 T1D association statistics with T2D association from the DIAGRAM consortium 4 . We first 103 determined shared effects among variants at known risk loci for both traits excluding the MHC 104 locus. There was an enrichment of nominal T1D association (P<.05) among 93 known T2D index 105 variants relative to matched background variants (obs=19.1%, exp=7.8%, binomial P=3.2x10 -4 ) 106 ( Figure 1A, Table S1 ). T2D index variants were also enriched for concordant direction of effect 107 on T1D (57/94, binomial P=.037), including among those with nominal T1D association (T1D 108 P<.05) (14/18, binomial P=.031) ( Figure 1B, Table S1 ). We found significant directional 109 concordance among the 14 variants with both nominal T1D association and same direction of 110 effect on T2D using summary data from UK Biobank (UKBB) (12/14, binomial P=.013). Despite 111 a net sharing in effects, several T2D loci had opposite effects on T1D risk including CTRB1 and 112 TCF7L2 (Figure 1B) . Conversely, there was less evidence for enrichment of nominal T2D 113 association (obs=12.2%, exp=7.3%, binomial P=.19) or concordant direction of effect (28/57, 114 binomial P=1) among 57 known T1D variants ( Figure 1A , Table S2 ). 115 116 We then determined the correlation between variant effects genome-wide on T1D and T2D risk. 117
In these analyses, we used LD-score regression on the set of HapMap3 variants common to T1D 118 and T2D association datasets (see Methods). We observed evidence for a positive correlation in 119 the effects of variants genome-wide on T1D and T2D risk (Rg=.14) ( Figure 1C) . A positive 120 correlation remained when performing these analyses using summary data of T1D and T2D from 121 the UK Biobank (T1D/T2D-UKBB Rg=.12, T1D-UKBB/T2D Rg=.23) ( Figure 1C) . We also 122 identified positive correlation with T1D risk when using T2D association data imputed from 123 different reference panels (GoT2D, HM2) (Rg=.18, Rg=.23) and from trans-ethnic cohorts (Rg=.22) 124 ( Figure 1C) . To limit the potential effects of misdiagnosed diabetes on these results, we first 125 P=3.1x10 -15 ), fasting glucose level (Rg=.57, P=4.2x10 -11 ), fasting insulin level (Rg=.48, P=2.9x10 -136 9 ), HOMA-IR (Rg=.55, P=1.9x10 -7 ), and body-mass index (BMI) (Rg=.48, P=3.9x10 -36 ), and 137 decreased birth weight (Rg=-.28, P=1.2x10 -8 ) (Figure 2A ). There was also evidence for a 138 correlation between T2D risk and increased proinsulin level (Rg=.22, P=.057) and male pubertal 139 size (Rg=.12, P=.14) although these estimates were not significant. For T1D, we observed a 140 correlation between T1D risk and increased fasting proinsulin (Rg=.23, P=.034) and fasting insulin 141 level (Rg=.17, P=.047) (Figure 2A) . We also observed evidence for a correlation between T1D 142 risk and decreased birth weight (Rg=-.09, P=.10), increased male pubertal size (Rg=.18, P=.11), 143 and increased fasting glucose level (Rg=.07, P=.32) although these estimates were not significant. 144
We did not observe correlation between T1D and BMI (Rg=-0.02, P=.52) or childhood obesity 145 (Rg=-0.02, P=.75), the latter previously identified as an instrumental variable for T1D risk 28 . 146
147
We determined the extent to which traits correlated with both T1D and T2D risk might be driven 148 through variants with shared effects on T1D and T2D. From genome-wide association data for 149 T1D and T2D, we extracted variants with the same direction of effect and tested these variants 150 for correlation to each trait using LD score regression. For both T1D and T2D, we observed 151 stronger correlations with increased fasting glucose level (T1D shared Rg=.43, T2D shared 152 Rg=.65), increased fasting insulin level (T1D shared Rg=.55, T2D shared Rg=.68), and decreased 153 birth weight (T1D shared Rg=.25, T2D shared Rg=.29) among variants with same direction of 154 effect (Figure 2B) . We observed less evidence for pronounced correlation between shared effect 155 T1D and T2D variants and fasting proinsulin level (T1D shared Rg=.33, T2D shared Rg=.28), and 156 male pubertal growth (T1D shared Rg=.26, T2D shared Rg=.16) ( Figure 2B) . 157 158 We next determined functional annotations enriched for T1D and T2D associated variants. We 159 used annotations of active enhancer and promoter elements in 98 cell types from the Epigenome 160 roadmap project 21 and annotations of protein-coding gene exons and UTRs from GENCODE 29 . 161
We tested for enrichment of each annotation for T1D and T2D risk using stratified LD score 162 regression 17 . There was evidence for positive enrichment genome-wide of both T1D and T2D 163 association for variants in pancreatic islet (T1D Z=1.02, T2D Z=2.67), adipose nuclei (T1D Z=.09, 164 T2D Z=1.52), CD19+ B cell (T1D Z=3.12, T2D Z=.31), CD184+ endoderm (T1D Z=.62, T2D 165 Z=1.25), and pancreas (T1D Z=.41, T2D Z=.62) regulatory elements ( Figure 2C) . We also 166 observed enrichments specific to each trait, most notably T1D association for immune regulatory 167 elements such as T cell (Z=4.67) and fetal thymus (Z=1.83) ( Table S4) . 168
Given enrichment of multiple cell-types for both T1D and T2D association, we next tested to what 170 extent these effects were driven through variants with same direction of effect on T1D and T2D. 171
We obtained LD-pruned variants nominally associated (P<.05) with both T1D and T2D and with 172 same direction of effect and tested for enrichment of overlap with each annotation compared to 173 random sets of matched variants (see Methods). We observed significant enrichment of overlap 174 with CD184+ endoderm (Fisher's P=.017), adipose nuclei (P=.018) and pancreatic islet (P=.040) 175 regulatory sites (Figure 2D) . We next repeated these analyses instead using variants with 176 opposite direction of effect on T1D and T2D. We observed significant overlap of opposite effect 177 variants with CD184+ endoderm (P=.031) and pancreatic islet regulatory elements (P=.020), 178
suggesting that these cell-types are enriched in variants with both shared and opposite effects on 179 T1D and T2D. 180
181
We next used association data to fine-map specific causal variants influencing T1D and T2D. For 182 T2D we compiled fine-mapping data of 93 signals from previous studies (see Methods). As fine-183 mapping data for all known T1D loci have not been previously reported, we used T1D association 184 statistics to fine-map 57 T1D risk signals excluding the MHC region. At each locus, we considered 185 the index variant for the locus and all variants in at least low LD (r 2 >.1). We then used a Bayesian 186 approach to calculate the posterior causal probability (PPA) for each variant, and 'credible sets' 187 of variants explaining 99% of the total PPA (see Methods, Figure 3A , Table S5 ). T1D credible 188 sets contained a median of 66 variants, and 15 loci had 25 or fewer credible set variants. We 189 compared fine-mapping for 34 loci common to our data and Immunochip fine-mapping 3 , and found 190 a strong correlation between T1D association for credible set variants (Pearson r=.93). Credible 191 set sizes at these 34 loci were larger in our data than for Immunochip (median=37, Immunochip 192 median=31), likely reflecting increased variant density. We also identified high probability variants 193 not covered in Immunochip credible sets for example at CTSH (rs12592898, PPA=.19). 194
195
Given fine-mapping of known T1D and T2D signals, we next determined genomic annotations of 196 candidate causal variants at these signals. For each signal, we calculated the cumulative PPA of 197 variants overlapping T1D/T2D enriched annotations including pancreas, adipose, endoderm and 198 immune cell regulatory elements as well as protein-coding exons. We then grouped signals 199 based on the resulting cumulative PPA values for each annotation (see Methods). For T1D, 200 signals mapped into distinct groups of immune cell regulatory elements (31 signals), pancreas 201 regulatory elements (6 signals), and coding exons (4 signals) as well as 15 un-annotated signals 202 ( Figure 3B) . For T2D, signals also mapped into distinct groups including pancreas regulatory elements (21 signals), adipose regulatory elements (15 signals), and coding exons (4 signals) 204 ( Figure S2 ). T1D pancreas signals were associated with T2D risk (median -log10(P)=1.37), 205 whereas other T1D groups did not show evidence for T2D association (Figure 3C) . Among T1D 206 signals in the pancreas group were those with known T2D association such as GLIS3 and CTRB1, 207 as well as others with nominal T2D association such as ERBB3. 208 209 Several loci have been reported to influence risk of both T1D and T2D, but whether risk signals 210 have shared or distinct causal variants is unknown. We cataloged 144 loci with known association 211 to either form of diabetes and tested for shared causal variants using Bayesian co-localization 212 (see Methods, Table S6 ). There was co-localization of risk signals (Pshared>.50) at three known 213 T1D and T2D loci CENPW (Pshared=.88), CTRB1 (Pshared=.88), and GLIS3 (Pshared=.62) as well as 214 evidence for putative co-localization of signals at known T2D loci BCL11A (Pshared=.73) and 215 THADA (Pshared=.68) ( Figure 4A ). All shared risk signals except for CTRB1 had the same 216 direction of effect on T1D and T2D risk. At RASGRP1, which has reported association to both 217 T1D and T2D, we found no evidence for either state (Pdistinct=.03, Pshared=.02) ( Table S5) . At 218 several loci including MTMR3 and ZMIZ1, there was evidence for two distinct T1D and T2D 219 signals (Pdistinct>.5) ( Figure 4A) . We fine-mapped causal variants at co-localized signals by 220 combining T1D and T2D evidence (see Methods). There was a reduction in credible set size at 221 shared loci, including fewer than 10 variants at GLIS3 (9 vars) and CTRB1 (8 vars) ( Figure 4B , 222 Figure S3 , Table S7 ). We further confirmed evidence (CLPP>.01) for shared causal variants at 223 the GLIS3 and CTRB1 signals using eCAVIAR (see Methods, Figure S3 , Table S7 ). 224
225
To understand mechanisms of how the shared T1D and T2D signals influence diabetes risk, we 226 examined quantitative trait associations at shared signals 24,30-32 . At GLIS3, risk alleles were 227 associated with increased fasting glucose level (rs10758593 Z=4.51) and decreased HOMA-B 228 (Z=-4.54) as well as decreased birth weight (Z=-2.27) (Figure 4C) . At CTRB1, risk alleles for T2D 229 were nominally associated with higher fasting glucose (rs8056814 Z=2.27) and decreased birth 230 weight (Z=-3.78). At CENPW, risk alleles were also nominally associated with higher fasting 231 glucose (rs4565329 Z=2.32) and decreased birth weight (Z=2.97), as well as increased male 232 pubertal size (Z=3.14), height (Z=13), and earlier age of menarche (Z=-8.9). Among putative 233 shared signals, variants at THADA were associated with increased fasting glucose level (Z=3.65) 234 and decreased HOMA-B (Z=-4.23). 235
Multiple shared T1D and T2D signals likely affect beta cell function, and thus we annotated 237 variants in islet regulatory sites at these signals. We used accessible chromatin sites merged 238 from ATAC-seq in six islet samples 33, 34 (Table S8) , chromatin states created from islet histone 239 modification ChIP-seq data 6,35 , islet transcription factor (TF) ChIP-seq sites 6 , and TF footprints 240 generated in islet ATAC-seq using CENTIPEDE 33 (see Methods). At GLIS3, rs4237150 241 (PPA=.20), rs10116772 (PPA=.15) and rs10814915 (PPA=.007) mapped in islet accessible 242 chromatin, active enhancer, and disrupted TF footprints, as well as islet TF ChIP-seq for 243 rs4237150 (Figure 4D , Table S7 ). At CTRB1, rs8056814 (PPA=.91) also mapped in islet 244 accessible chromatin, active enhancer and disrupted TF footprints ( Figure S4 , Table S7 ). 245
246
We tested these shared variants at GLIS3 and CTRB1, and another nearby GLIS3 candidate 247 variant rs6476839, for effects on islet regulatory activity. We cloned sequence surrounding 248 variant alleles into reporter vectors in both forward and reverse orientations, and transfected 249 constructs into the islet cell line MIN6. As rs10116772 and rs10814915 were within 3bp, we 250 cloned these variants in the same construct. At GLIS3, there was a significant allelic difference 251 in enhancer activity in both orientations for rs4237150 (Two-sided t-test Fwd P=1.2x10 -4; Rev 252 P=.024), as well as evidence in one orientation only for the rs10116772+rs10814915 and 253 rs6476839 constructs ( Figure 4E ). We further identified evidence for allelic imbalance in islet 254
ChIP-seq reads from samples estimated to be heterozygous for these GLIS3 variants (see 255
Methods; Figure S5 ). At CTRB1, we observed significant allelic difference in repressor activity 256 for rs8056814 (Fwd P=.017 ; Rev P=6.7x10 -4 ; Figure S4 ). This is unlikely to explain a positive correlation between T1D and T2D given that we observed no 264 enrichment of T2D association or concordance in effect direction among known T1D variants, 265 even among large effect T1D variants, and the correlation remained when using clinically defined 266 T2D in the WTCCC with no T1D relatives, negative anti-GAD, and >1 year from diagnosis to 267 insulin treatment. Misdiagnosis of T2D as T1D is also an unlikely explanation of the positive 268 correlation as it remains when using clinically defined T1D in the WTCCC with onset <17, insulin treatment from diagnosis for >6 months, and no monogenic diabetes, or when removing obese 270 individuals from T1D cohorts. Furthermore, we found little evidence for directional consistency 271 among largest effect T2D variants. 272
273
Reports have argued that islet dysfunction underlies shared etiology of T1D and T2D 12 . Our 274 findings support a role for shared variants at GLIS3 in islet function, where risk alleles were 275 associated with increased fasting glucose level and decreased beta cell function. In addition, 276 multiple shared risk variants at GLIS3 had allelic effects on islet enhancer activity and one was 277 predicted to bind the glucocorticoid receptor, which is involved in diabetes-relevant inflammatory 278 response 37 . The mechanism of how these variants influence diabetes risk through regulation of 279 GLIS3 and/or other genes in islets remains to be uncovered. Putative shared risk signals at 280 THADA were associated with increased glucose level and decreased beta cell function, in line 281 with a previous report 38 , and variants at BCL11A have been reported to affect beta cell function 38 . 282 Candidate genes at these loci are involved in apoptotic and stress-related processes 39,40 and 283 therefore altered activity could contribute to a fragile beta cell phenotype. Genome-wide, T1D 284 and T2D associated variants were enriched in islet regulatory elements and correlated with 285 increased fasting glucose level. Given the role of islet stress response in shared risk, studies 286 mapping the islet epigenome and gene expression in diabetogenic stress conditions will help 287 uncover additional relevant islet regulatory programs. 288 289 Shared variants at the CTRB1 locus have opposite effects on T2D and T1D risk and have allelic 290 effects on islet regulatory activity, in line with a previous report correlating risk variants with 291 CTRB1/2 expression in pancreas and pancreatic islets 13 . The variant affects a site with apparent 292 repressive activity in islets. Other loci have evidence for opposite effects on T1D and T2D such 293 as TCF7L2, where T2D risk variants affect islet regulatory activity 7 , ZZEF1, and a recently 294 identified association at HLA-DRB5 5 . Heterogeneity in effect direction at specific loci has been 295 observed in other contexts, for example, between T2D and cardiovascular disease and T2D and 296 birth weight 5,26 . We further observed enrichment of nominally associated variants with opposite 297 effects on T1D and T2D in islet regulatory elements, suggesting the potential of a broader 298 mechanistic role for aspects of pancreatic and islet function in opposed risk of T1D and T2D. The 299 specific mechanisms, however, of how CTRB1, TCF7L2 and other loci encode opposing risk is 300 currently unclear and may involve multiple genes and other cell types. 301
Another shared mechanism of T1D and T2D pathogenesis is through obesity and insulin 303 resistance. The 'accelerator' hypothesis posits that weight gain and insulin resistance exacerbate 304 beta cell stress and T1D progression in a manner similar to T2D pathogenesis 11 . We identified 305 support for this hypothesis through a correlation between increased fasting insulin level and T1D 306 and T2D risk. We also identified enrichment of T1D and T2D variants for adipose and B cell 307 regulatory elements, cell types both involved in insulin resistance. We did not find significant 308 correlation between T1D risk and BMI, or association with large effect obesity loci such as FTO. 309
A recent study identified a causal relationship between childhood obesity and T1D risk, supporting 310 a role for adolescent growth in T1D pathogenesis 28 , though we did not observe a genome-wide 311 correlation. There was, however, a positive correlation with male pubertal phenotypes, in line 312 with increased prevalence of T1D in males in early adulthood 41 , and risk variants at the CENPW 313 locus were associated with male pubertal growth, height and age of menarche 31,32 . This supports 314 a role for insulin resistance and growth in the shared etiology of T1D and T2D. 315
316
We also observed evidence for correlations with other traits, such as between increased T1D and 317 T2D risk and decreased birth weight and increased proinsulin level. Previous studies have 318 reported a correlation between low birth weight and increased T2D risk 26,42 , although the potential 319 link between birth weight and T1D risk is unclear 43 . Furthermore, variants in endoderm regulatory 320 sites were enriched for T1D and T2D association, suggesting potential shared effects on 321 developmental regulatory processes. Proinsulin is an autoantibody in T1D and higher proinsulin 322 level could contribute to increased risk of developing T1D 44 . Conversely, impaired insulin 323 processing is observed in beta cell dysfunction and thus could also represent a consequence of 324 disease progression 45 . Additional studies will be needed to determine causal relationships 325 between proinsulin level or birth weight and diabetes risk and the direction of these relationships. 326
327
In total, our findings support shared risk involving variants affecting islet function as well as insulin 328 resistance, growth and development, in the etiology of T1D and T2D. Further studies will help 329 establish the cellular mechanisms of these effects and their role in diabetes pathogenesis. 330 331 Methods 332 333
T1D sample collection 334
For the type 1 diabetes GWAS, we compiled publicly available genotype-level data for case and phs000018.v2.p1), DCCT-EDIC (dbGAP: phs000086.v3.p1), WTCCC1 46 , and WTCCC2, which 337 were either genotyped on Affymetrix or Illumina platforms (Table S1 ). Because the GoKIND/GAIN 338 dataset contained family trios, we extracted only the proband samples. From the WTCCC1 339 samples, we used the T1D cohort as cases and the 1958 Birth Cohort (58BC), UK National Blood 340 Service (NBS), and bipolar disorder (BP) cohorts as controls. Unlike a previous study for T1D 47 , 341 we did not include type 2 diabetes or hypertension from WTCCC1 as controls. From the WTCCC2 342 samples, we used control cohorts from the UK National Blood Service. 343
344

T1D quality control and imputation 345
We used the recommended individual and variant exclusion lists where available for 58BC, NBS, 346 WTCCC1 T1D and BP. We used phenotype files for GoKIND/GAIN and DCCT-EDIC to exclude 347 samples that were not reported of Caucasian ancestry. We used PLINK 48 (https://www.cog-348 genomics.org/plink2) to perform PCA with 1000 Genomes Project (1KGP) samples to identify and 349 remove outliers that did not overlap European 1KGP samples on PC1 and PC2. We used PLINK 350 to calculate identity-by-descent (IBD) values between individuals. Pairs of individuals with at least 351 second-degree relationships (IBD>.2) were pruned in a manner such that only one related 352 individual was retained. For the NBS samples that overlapped between Affymetrix and Illumina 353 platforms, we prioritized the samples genotyped on the Illumina platform. For each cohort, we 354 filtered out variants with less than 95% call rate, less than 1% minor allele frequency (MAF), and 355 extreme Hardy-Weinberg equilibrium values (P<1x10 -5 ). We also removed individuals with more 356 than 5% missing genotypes. We then combined cohorts that were genotyped on similar platforms. 357
After filtering steps, the total number of individuals available was 15,043, including 8,967 cases 358 and 6,076 controls (Table S3 ). We imputed 347,083 (Affymetrix) and 500,096 (Illumina) 359 autosomal variants separately into the HRC panel r1.1 using the Michigan Imputation Server 49 , 360 resulting in data for 39,117,105 variants. We excluded variants after imputation that had an 361 imputation quality (R 2 ) less than 0.3, leaving 23,385,104 (Affymetrix) and 25,294,976 (Illumina) 362 well-imputed variants. 363
T1D genome-wide association and meta-analysis 365
We used the firth bias-corrected logistic likelihood ratio test as implemented in EPACTS 366 (https://genome.sph.umich.edu/wiki/EPACTS) to test variants for association to T1D separately 367 for Affymetrix and Illumina combined cohorts. We used PLINK to LD prune genotyped variants to 368 create a set of independent variants. We then used PLINK to perform principal component PCs as covariates, set a lower MAF threshold of 0.005, and used genotype dosages for 371 association testing. For triallelic SNPs and cases where multiple variants mapped to the same 372 genomic coordinates, we kept the variant with the highest MAF. We then used inverse-variance 373 meta-analysis as implemented in METAL 50 on association results for 8,720,060 (Affymetrix) and 374 8,778,018 (Illumina) variants, keeping variants that were tested on both platforms. We further 375 removed genotyped variants that had an empirical R 2 (ER 2 <.8) for either cohort and all variants 376 in at least moderate LD (r 2 >.5) with these variants. A total of 8,491,085 variants remained for 377 downstream analyses. 378
379
To address the potential for misdiagnosed T2D cases in the T1D GWAS, we used phenotype 380 data to remove 278 T1D cases with body-mass index (BMI)>30 from the DCCT and 381
GoKIND/GAIN cohorts. We then re-ran the GWAS meta-analyses using the above methods. 382
383
WTCCC genome-wide association 384
We collected genotype data for a case cohort of T2D, and control cohorts from NBS and 58BC 385 from the WTCCC1 study 46 . We used sample exclusion lists to remove duplicate, related, or non-386
Caucasian ancestry samples and SNP exclusion lists to remove poorly genotyped variants. Prior 387 to imputation, we also filtered out variants with less than 95% call rate, less than 1% MAF, and 388 extreme Hardy-Weinberg equilibrium values (P<1e -5 ). We imputed 412,388 genotyped variants 389 from 1,924 T2D case samples and 2,939 control samples together into the HRC panel r1.1 using 390 the Michigan imputation server. After excluding variants with R 2 < 0.3, we retained 22,520,888 391 well-imputed variants. We filtered out artifacts by excluding genotyped variants with ER 2 <0.8 and 392 all variants in at least moderate LD (r 2 >.5) with these variants. We used the firth bias-corrected 393 logistic likelihood ratio test as implemented in EPACTS to test variants with MAF > 0.005 for 394 association, using the top 3 PCs as covariates. We finally extracted summary statistics for 395 For each trait, we formatted summary statistics to retain only variants in HapMap3 and correctly 440 orient variant alleles. We then ran LD score regression on the resulting formatted files using 441 default LD scores. 442 443
Genomic enrichment analyses 444
We considered active enhancer and promoter site annotations for 98 cell types from the 445 Epigenome Roadmap project 21 , along with annotations for coding exons from GENCODE 29 . We 446 used stratified LD-score regression 17 to identify annotations that were enriched for signal in T1D 447 and T2D association data. Stratified LD-score regression is a multiple regression, where the chi-448 squared statistics for a trait are regressed on LD-scores computed using variants from each of a 449 set of functional annotations, and the estimated parameters quantify the relative contribution of 450 each annotation to the total heritability. 451
452
For the five cell-types with positive enrichment for both T1D and T2D association (pancreatic 453 islets, pancreas, adipose, CD19+ B cells, and CD184+ endoderm), we tested whether these 454 annotations were enriched in variants with shared or opposite effects on T1D and T2D. We 455 identified variants with P<.05 for both T1D and T2D association and in 1000 Genomes phase 3 456 data. For each of these variants i, we computed zi,T1D = b i,T1D / SE i,T1D and z i,T2D = b i,T2D / SE i,T2D. 457
We sorted them by the value of | zi,T1D + zi,T2D | for LD-pruning purposes. After sorting, we pruned 458 these variants using the SNPclip tool of LDlink 54 using EUR populations, a R 2 >0.1 and MAF>0.01, 459 resulting in 3856 and 2254 independent shared and opposite variants, respectively. We then 460 generated sets of randomized, matched SNPs using SNPsnap 55 . We tested shared and opposite 461 variants for enriched overlap compared to the average overlap across matched variant sets using 462 a one-sided Fisher exact test. 463 464
Fine-mapping of causal variant sets 465
We used effect and standard error estimates to calculate a Bayes Factor 56 for each variant. We 466 obtained 58 known loci for T1D from Immunobase and excluded the MHC locus (Table S2) . We 467 extracted the previously reported index variants and used PLINK to calculate r 2 values between 468 57 index variants and all common variants (MAF>.5) within a 5 MB window as done in a previous 469 study 8 . We defined credible sets of variants for each locus as variants with r 2 >.1 with the index 470 variant. For each locus, we calculated the posterior probability of association (PPA) for each locus. We then calculated the 99% credible set by taking the set of variants for each locus that 473 added up to 99% PPA. We compared our T1D credible sets to previously published Immunochip 474 credible sets 3 by extracting 34 common loci between both studies. From the Immunochip study, 475 we extracted only the primary signals. To directly compare p-values, we filtered for variants 476 covered by both studies with non-missing p-values and calculated the Pearson correlation. To 477 identify high probability variants not in Immunochip credible sets, we extracted variants from the 478 34 loci that were not in the Immunochip primary signal credible set and sorted by PPA. 479 480
Genomic annotations at fine-mapped signals 481
We considered active regulatory site annotations for cell-types enriched for T1D/T2D association 482 along with annotations for coding exons and UTR regions from GENCODE 29 . For T1D we used 483 fine-mapping data from 57 signals as described above. For T2D we used published fine-mapping 484 data for 93 primary signals from Metabochip, GoT2D and DIAGRAM 1000G studies. At each 485 signal, we calculated a cumulative posterior causal probability (PPA) for each annotation as the 486 sum of PPA values for variants overlapping that annotation. We then assigned T1D/T2D signals 487 to groups based on the highest cumulative PPA value across annotations, considering signals 488 with a cumulative PPA value less than .1 for all annotations as 'un-annotated'. For each T1D 489 group we then calculated the median association of signals in the group with T2D, and for each 490 T2D group we calculated the median association with T1D. 491
492
Risk signal co-localization 493
We used a Bayesian co-localization method to determine loci at which T1D and T2D association 494 data showed evidence of a causal variant shared by both traits 57 . At a given locus, the method 495 takes as inputs Bayes Factors of association from two datasets and a specification of the prior 496 probability that each is causal for one or both traits. From these a posterior probability (PP) is 497 computed for each of five hypotheses: 498 499 H0: The locus contains no variant causal for either trait 500 H1: The locus contains a variant causal for trait 1 but none causal for trait 2 501 H2: The locus contains a variant causal for trait 2 but none for trait 1 502 H3: The locus contains a variant causal for trait 1 and an independent variant causal for trait 2 503 H4: The locus contains a variant causal for both H1 and H2. 504
We used the default prior assumption that all variants at a locus are equally likely to be causal. 506
This model has two important limitations: It assumes each locus has at most one causal variant, 507 and the distinction between H3 and H4 may be confounded by cases of high LD. We considered 508 the prior probability that a variant is associated with T1D or T2D as 1x10 -4 and the prior probability 509 that a variant is associated with both traits as 1x10 -5 . 510
511
We collected 93 T2D loci and 56 T1D loci, of which five have overlapping coordinates (CENPW, 512 GLIS3, RASGRP1, CTRB1, MTMR3), for a total of 144 loci ( Supplemental Table 3 ). At each 513 locus, we obtained a reported index variant and then extracted all variants in a 500kb window. 514
For each variant, we calculated a Bayes Factor for T1D and T2D separately using the approach 515 of Wakefield 56 . We then applied the co-localization test to compare T1D and T2D Bayes Factors, 516 and considered loci with H4 > .50 as shared. For loci with evidence for a shared risk variant, we 517 then fine-mapped variants causal for the shared signal. For each locus, we multiplied T1D and 518 T2D Bayes Factors at each variant, and then calculated the posterior causal probability (PPA) as 519 the Bayes Factor divided by the sum of all variant Bayes Factors across the locus. We further 520 calculated a cumulative PPA (cPPA) as the sum of PPA values for variants overlapping an 521 annotation at a given locus. 522
523
To validate loci with evidence for a shared causal variant we further applied eCAVIAR, a co-524 localization method capable of modeling multiple causal variants 58 . For each locus, we chose a 525 window of 100 variants on either side of the variant with the strongest combined T1D and T2D 526 evidence. We provided Z-scores of T1D and T2D association together with pairwise LD statistics 527 of European samples in 1000 Genomes Project v3 data for all variants within the window to 528 eCAVIAR using default settings. For each variant in the window, eCAVIAR computed a co-529 localization posterior probability (CLPP), the probability that the variant is causal for the local 530 signal in both traits. We considered loci to be co-localized using this approach with at least one 531 variant with CLPP > 0.01 as recommended in the original study. 532 533 For quantitative trait association at shared risk variants, we obtained the most likely causal variant 534 from combined T1D and T2D evidence. We extracted summary statistics for each trait and 535 calculated a signed Z-score for the risk allele using effect size and standard error estimates. 536
We utilized ATAC-seq data generated from four primary pancreatic islet samples as described in 539 a separate study 59 . For each sample, we trimmed adaptor sequences from the reads with 540 trim_galore (https://github.com/FelixKrueger/TrimGalore). The resulting sequences were aligned 541 to sex-specific hg19 reference genomes using bwa mem 60 . We filtered reads to retain those in 542 proper pairs and with mapping quality score greater than 30. We then removed duplicate and 543 non-autosomal reads. We called sites individually for each sample with MACS2 61 at a q-value 544 threshold of .05 with the following options "-no-model", "-shift -100", "-extsize 200". We 545 removed sites that overlapped genomic regions blacklisted by the ENCODE consortium 20 . We 546 merged sites from these 4 samples and two previously generated in islets 33 with bedtools 62 to 547 obtain a comprehensive set of ATAC-seq peaks in human islets. 548
549
We used islet chromatin states described separately 34 . In brief, we used previously published 550 data 6,35 from ChIP-seq assays generated in islets and for which there was matching input 551 sequence from the same sample. For each assay and input, we aligned reads to the human 552 genome hg19 using bwa samse and bwa aln 60 with a flag to trim reads at a quality threshold of 553 less than 15. We converted the alignments to bam format and sorted the bam files. We then 554 removed duplicate reads, and further filtered reads that had a mapping quality score below 30. 555
Sequence data from the same assay in the same sample were then pooled. We defined 556 chromatin states from ChIP-seq data using ChromHMM 63 with a 9 state model. We assigned the 557 resulting states names based on the resulting patterns. 558
559
ATAC-seq footprint analysis 560
To identify haplotype-aware motifs within ATAC-seq footprints overlapping accessible chromatin 561 sites, we searched accessible chromatin sites from four ATAC-seq samples for instances of motifs 562 from JASPAR, SELEX, ENCODE and de novo motifs identified in our data 64 . We used 563 vcf2diploid 65 (https://github.com/abyzovlab/vcf2diploid) to create individual-specific diploid 564 genomes by mapping our phased, imputed genotypes onto hg19 using only SNPs and ignoring 565 indels. Then, we used fimo 66 to scan the personalized genomes for our compiled database of 566 motifs, limiting the sequences scanned to those derived from islet accessible chromatin. For fimo, 567 we used the default parameters for p-value threshold (1x10 -4 ) and a background GC content of 568 40.9% based on hg19. 569 570 CENTIPEDE 67 was used to discover footprint sites for each motif, using the discovered motif atactk (https://github.com/ParkerLab/atactk) to calculate a cut-site matrix that contained counts of 573 the number of Tn5 integrations within a window defined by ±100 bp from each motif occurrence 574 for both forward and reverse strands. This cut-site matrix was provided as input to CENTIPEDE 575 along with regions for each motif occurrence to model the posterior probability that a given motif 576 occurrence was bound by a TF. We defined footprints for a given motif as regions that had a 577 posterior probability ≥ 0.99. We combined footprints from our samples with a previously published 578 set of footprints in pancreatic islets 33 . 579
580
We further identified variants predicted to disrupt each footprint 4 . We calculated the entropy score 581 for a variant position in a footprint using the position frequency matrix for each motif. 
Allelic imbalance analysis 620
We collected ChIP-seq data from assays in primary islet cells from multiple sources 6,35,68-71 . We 621 aligned sequence data using bwa samse 60 , filtered out mitochondrial reads, and removed 622 duplicates using Picard software. For each sample we applied QuASAR 72 to obtain estimated 623 genotypes. A total of 6 samples were determined to be heterozygous at rs4237150 with probability 624 of being homozygous < 10 -4 . For these samples we also inferred heterozygosity at rs10116772, 625 due to high linkage and by imputation into 1000 Genomes v3 variants via the Michigan Imputation 626 Server 49 . Across these 6 samples, a total of 8 datasets had more than 5 reads overlapping 627 rs4237150 -FOXA2 (1), H3K27ac (3), PDX1 (2), NKX6-1 (2). We applied WASP 73 to each 628 dataset to correct for reference mapping bias. We then pooled read counts for risk and protective 629 alleles at rs4237150 and rs10116772 and applied a two-sided binomial test for allelic imbalance. E   MTMR3  ZMIZ1  INS  KLF14  ARL15  4q32  PLEKHA1  HNF1B  PPARG  CDC123  ACSL1  ST6GAL1  WFS1  TCF7L2  TP53INP1  KLHDC5  MACF1  ZZEF1  GLIS3  THADA  BCL11A  CTRB1 TMEMPC   PPARG  ZBED3  NOTCH2  RBMS1  ANKRD55  ADCY5  SRR  AP3S2  ZZEF1  GRK5  ADAMTS9  THADA  PEPD  FTO  SLC16A13  SSR1  APOE  CILP2  KCNJ11  HNF4A  CMIP  ZMIZ1  ST6GAL1  GPSM1  HMG20A  HSF1  IGF2BP2  PTPRD  RASGRP1  BCL2  TP53INP1  PLEKHA1_ARMS2  LPP  PRC1  ABO  JAZF1  BCL11A  CDC123  ACSL1  TCF7L2  SPRY2  MACF1  ANK1  TMEM154  CENTD2  CTBP1  HNF1A.cond1  KCNK16  BCAR1  GLIS3  KLHDC5  GCK  SLC30A8  PROX1  HNF1B  MTMR3_HORMAD2  GRB14  TLE1  ARL15  KLF14  ZFAND6  VPS26A  GLP2R  FAF1  MPHOSPH9  ZFAND3  HSD17B12  C2CD4A 
